The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Interested in Johnson & Johnson? Here are five stocks we like better.
Johnson & Johnson expects MedTech growth at the high end of its 5%–7% operational market-growth target through 2027, driven by a greater focus on cardiovascular products, including Abiomed, Shockwave and electrophysiology.
The company is preparing to separate its orthopedics business around mid-2027 and expects to clarify whether it will pursue a sale, spin-off or another structure before year-end.
J&J is expanding its cardiovascular and robotics pipeline with new pulsed-field ablation catheters and the OTTAVA surgical robot, while maintaining its outlook despite international competition, China procurement risks and geopolitical uncertainty.